Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial - PubMed (original) (raw)
Clinical Trial
doi: 10.1111/j.1464-5491.2005.01473.x.
S Pampanelli, F Porcellati, A Avogaro, E Bosi, G Petrella, S Squatrito, S Furneri, G Marra, L Vitali, M Previti, D Cucinotta
Affiliations
- PMID: 15842516
- DOI: 10.1111/j.1464-5491.2005.01473.x
Clinical Trial
Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial
G Perriello et al. Diabet Med. 2005 May.
Abstract
Aims: This randomized, multi-centre, double-blind, stratified, two period, cross-over trial was undertaken to assess the pharmacokinetics and pharmacodynamics of insulin aspart injected immediately before compared with regular human insulin injected 30 min before a Mediterranean-style meal in 37 (23 M, 14 F) patients with Type 2 diabetes.
Methods: Insulin aspart or regular human insulin was given subcutaneously (0.15 U/kg) in random sequence, using a double-dummy technique (at one visit: human regular insulin at t=-30 min and placebo at t=0; at the other visit: placebo at t=-30 min and aspart insulin at t=0). Serum glucose and insulin concentrations (15 points) were measured after each meal for 240 min.
Results: Post-prandial glycaemic excursions were 20% lower with insulin aspart (IAsp) compared with regular human insulin (HI) treatment [ratio (Iasp/HI)=0.80, CI=(0.66-0.98), P=0.034]. The maximum serum glucose (SG) concentration was similar for the two treatments (P=NS). The (median) time to maximum SG was 25 min shorter for IAsp compared with HI (P=0.048). Maximum serum insulin concentration was higher after IAsp compared with HI (P=0.023) as well as the area under the 4-h serum insulin curve (P=0.006). Furthermore, the time to maximum serum insulin concentration was 27 min shorter after IAsp (P=0.039), even though IAsp was injected 30 min after HI. No adverse events occurred during the trial.
Conclusions: In patients with Type 2 diabetes a more favourable insulin profile and a better glycaemic control were found with IAsp injected immediately before compared with HI injected 30 min before a Mediterranean-style meal.
Similar articles
- Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
Gredal C, Rosenfalck A, Dejgaard A, Hilsted J. Gredal C, et al. Diabetes Res Clin Pract. 2008 May;80(2):293-8. doi: 10.1016/j.diabres.2007.12.023. Epub 2008 Mar 4. Diabetes Res Clin Pract. 2008. PMID: 18304675 Clinical Trial. - The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes.
Krones R, Schütte C, Heise T. Krones R, et al. Diabetes Obes Metab. 2009 Jan;11(1):41-4. doi: 10.1111/j.1463-1326.2008.00988.x. Diabetes Obes Metab. 2009. PMID: 19120432 Clinical Trial. - Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
Danne T, Råstam J, Odendahl R, Näke A, Schimmel U, Szczepanski R, Moeller J, Deiss D. Danne T, et al. Pediatr Diabetes. 2007 Oct;8(5):278-85. doi: 10.1111/j.1399-5448.2007.00261.x. Pediatr Diabetes. 2007. PMID: 17850471 Clinical Trial. - Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
Lindholm A, Jacobsen LV. Lindholm A, et al. Clin Pharmacokinet. 2001;40(9):641-59. doi: 10.2165/00003088-200140090-00002. Clin Pharmacokinet. 2001. PMID: 11605714 Review. - Insulin aspart: promising early results borne out in clinical practice.
Heller S, Kurtzhals P, Verge D, Lindholm A. Heller S, et al. Expert Opin Pharmacother. 2002 Feb;3(2):183-95. doi: 10.1517/14656566.3.2.183. Expert Opin Pharmacother. 2002. PMID: 11829732 Review.
Cited by
- Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.
Hövelmann U, Raiter Y, Chullikana A, Liu M, Donnelly C, Lawrence T, Sengupta N, Cl G, Ranganna G, Barve A. Hövelmann U, et al. Diabetes Obes Metab. 2021 Dec;23(12):2670-2678. doi: 10.1111/dom.14519. Epub 2021 Aug 25. Diabetes Obes Metab. 2021. PMID: 34378861 Free PMC article. Clinical Trial. - Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide.
Kildegaard J, Buckley ST, Nielsen RH, Povlsen GK, Seested T, Ribel U, Olsen HB, Ludvigsen S, Jeppesen CB, Refsgaard HHF, Bendtsen KM, Kristensen NR, Hostrup S, Sturis J. Kildegaard J, et al. Pharm Res. 2019 Feb 11;36(3):49. doi: 10.1007/s11095-019-2578-7. Pharm Res. 2019. PMID: 30746556 Free PMC article. - Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.
Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, Gerlach FM. Fullerton B, et al. Cochrane Database Syst Rev. 2018 Dec 17;12(12):CD013228. doi: 10.1002/14651858.CD013228. Cochrane Database Syst Rev. 2018. PMID: 30556900 Free PMC article. - Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.
Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, Plank J, Pieber TR, Gerlach FM. Fullerton B, et al. Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161. Cochrane Database Syst Rev. 2016. PMID: 27362975 Free PMC article. Review. - Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience.
Hermansen K, Bohl M, Schioldan AG. Hermansen K, et al. Drugs. 2016 Jan;76(1):41-74. doi: 10.1007/s40265-015-0500-0. Drugs. 2016. PMID: 26607485 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous